Sign up
Log in
12 Health Care Stocks Moving In Tuesday's Intraday Session
Share
Listen to the news

Gainers

  • Acurx Pharmaceuticals (NASDAQ:ACXP) shares rose 117.3% to $0.67 during Tuesday's regular session. The market value of their outstanding shares is at $15.6 million.
  • Verve Therapeutics (NASDAQ:VERV) stock rose 78.95% to $11.22. The market value of their outstanding shares is at $1.0 billion.
  • Eyenovia (NASDAQ:EYEN) shares rose 67.34% to $4.97. The company's market cap stands at $14.3 million.
  • Salarius Pharmaceuticals (NASDAQ:SLRX) shares moved upwards by 58.35% to $0.99. The company's market cap stands at $2.1 million.
  • Galectin Therapeutics (NASDAQ:GALT) stock increased by 55.03% to $2.31. The market value of their outstanding shares is at $146.2 million.
  • Beyond Air (NASDAQ:XAIR) shares moved upwards by 26.67% to $0.23. The company's market cap stands at $20.0 million. As per the press release, Q4 earnings came out today.

Losers

  • Adial Pharmaceuticals (NASDAQ:ADIL) stock declined by 27.6% to $0.24 during Tuesday's regular session. The company's market cap stands at $2.0 million.
  • Dyne Therapeutics (NASDAQ:DYN) shares declined by 21.55% to $10.84. The market value of their outstanding shares is at $1.2 billion.
  • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares decreased by 19.24% to $0.84. The company's market cap stands at $2.4 million.
  • Basel Medical Group (NASDAQ:BMGL) shares declined by 17.1% to $2.57. The company's market cap stands at $48.2 million.
  • Helius Medical Tech (NASDAQ:HSDT) stock decreased by 15.53% to $0.32. The company's market cap stands at $1.0 million.
  • Healthcare Triangle (NASDAQ:HCTI) stock decreased by 14.97% to $0.02. The market value of their outstanding shares is at $9.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.